Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock
NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total transaction of $102,235.00. Following the completion of the transaction, the senior vice president now directly owns 16,270 shares of the company’s stock, valued at approximately $475,246.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NxStage Medical, Inc. (NASDAQ NXTM) traded up 0.10% during mid-day trading on Tuesday, hitting $29.23. 1,246,143 shares of the company traded hands. The stock’s market capitalization is $1.93 billion. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80. The firm has a 50-day moving average of $25.09 and a 200-day moving average of $25.86.
NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.03) earnings per share. On average, equities analysts predict that NxStage Medical, Inc. will post ($0.04) earnings per share for the current year.
NXTM has been the subject of a number of analyst reports. Northland Securities downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 4th. Canaccord Genuity reissued a “buy” rating and issued a $32.00 price objective on shares of NxStage Medical in a research report on Monday, May 8th. BTIG Research reissued a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a research report on Wednesday, May 10th. Jefferies Group LLC decreased their price objective on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Finally, Craig Hallum initiated coverage on shares of NxStage Medical in a research report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price objective for the company. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.29.
Several hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new position in NxStage Medical during the fourth quarter valued at $11,841,000. Teachers Advisors LLC raised its position in NxStage Medical by 3.8% in the fourth quarter. Teachers Advisors LLC now owns 116,182 shares of the medical device company’s stock valued at $3,045,000 after buying an additional 4,257 shares during the last quarter. Capital Impact Advisors LLC bought a new position in NxStage Medical during the first quarter valued at $1,194,000. Nationwide Fund Advisors raised its position in NxStage Medical by 551.0% in the first quarter. Nationwide Fund Advisors now owns 258,975 shares of the medical device company’s stock valued at $6,948,000 after buying an additional 219,196 shares during the last quarter. Finally, Sit Investment Associates Inc. raised its position in NxStage Medical by 29.1% in the first quarter. Sit Investment Associates Inc. now owns 37,450 shares of the medical device company’s stock valued at $1,005,000 after buying an additional 8,450 shares during the last quarter. Institutional investors own 91.82% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.